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TGFb signaling Smads (Smad2, 3, and 4) were suspected tumor suppressors soon after their discov-
ery. Nearly two decades of research conﬁrmed this role and revealed other divergent and cancer-
speciﬁc functions including paradoxical tumor promotion effects. Although Smad4 is the most
potent tumor suppressor, its functions are highly context-speciﬁc as exempliﬁed by pancreatic can-
cer and head-and-neck cancer: in pancreatic cancer, Smad4 loss cannot initiate tumor formation
but promotes metastases while in head-and-neck cancer Smad4 loss promotes cancer progression
but also initiates tumor formation, likely through effects on genomic instability. The differing con-
sequences of impaired Smad signaling in human cancers and the molecular mechanisms that
underpin these differences will have important implications for the design and application of novel
targeted therapies.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Mammalian Smads were discovered in 1996 as the intracellular
signaling mediators of transforming growth factor b (TGFb) and
bone morphogenic protein (BMP) superfamily molecules and were
named after their non-mammalian homologs (the Sma genes of
Caenorhabditis elegans and the Mad (Mothers against decapenta-
plegic) gene from Drosophila) [1–3]. Smads regulate a variety of
critical processes including embryonic development, ﬁbrosis,
tumor development, immune function, and wound healing [4].
TGFb/BMP ligands initiate intracellular actions through transmem-
brane receptors that phosphorylate intracellular signalingchemical Societies. Published by E
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ng).molecules of the Smad family [5]. TGFb signaling is mediated by
receptor-speciﬁc Smads2/3 while BMP signaling is mediated by
receptor-speciﬁc Smads1/5/8 (Fig. 1). Phosphorylated receptor
Smads heterotrimerize with the common Smad (Smad4) and trans-
locate into the nucleus where they bind Smad binding elements
(SBEs) within the regulatory elements of TGFb/BMP responsive
genes [5]. Inhibitory Smads (Smad6 and Smad7) are also upregu-
lated after TGFb/BMP ligand binding, antagonize receptor-speciﬁc
Smad actions through a variety of mechanisms, and serve as an
endogenous negative feedback system to receptor Smad signaling
[6]. Smad binding at SBEs modulates gene expression though
recruitment of cell- or tissue-speciﬁc co-activators or co-repressors
to target gene promoters [5,7].
Because TGFb inhibits epithelial cell growth and promotes
differentiation, defects in TGFb/BMP signaling frequently promote
tumor growth, and numerous molecules in these pathways includ-
ing TGFbRI, TGFbRII, and Smad4 are established tumor suppressors
[8]. However, epithelial cells with impaired TGFb signaling fre-
quently release additional TGFb into the tumor microenvironment
which can paradoxically promote tumor growth and progression
by stimulating angiogenesis and inﬂammation within the stromal
compartment where TGFb signaling remains intact [9]. TGFb/BMP
ligands can also signal through non-canonical pathways including
ERK, p38/JNK (c-jun activated kinase), Rho/Rac, and
phosphatidylinositol-3-kinase (PI3K)/AKT; these pathways can be
independent of, or cooperate with, Smad signaling [10].lsevier B.V. All rights reserved.
Fig. 1. TGFb/BMP signaling. TGFb/BMP ligands mediate their signals through Smad family members.
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growth arrest [11], these molecules were suspected tumor sup-
pressors soon after their discovery. For Smad4, this role was clearly
substantiated by the identiﬁcation of Smad4 as ‘‘Deleted in Pancre-
atic Cancer 4 (DPC4)’’ which lies within a region of chromosome
18q frequently lost in pancreatic cancer [12] and the observation
that germ-line Smad4 mutations cause juvenile polyposis (JP), a
condition characterized by intestinal polyp formation early in life
and a lifetime gastrointestinal cancer risk of 50% [13]. Studies
in the past two decades have shown that Smad signaling is highly
tissue and tumor speciﬁc. This review compares and contrasts the
role of Smad4 loss in cancers arising from simple epithelia (as
exempliﬁed by pancreatic cancer) with squamous carcinomas aris-
ing from stratiﬁed epithelia (as exempliﬁed by head-and-neck and
esophageal cancer) to highlight the different consequences of im-
paired Smad signaling in human cancer.
2. The role of Smad4 loss in pancreatic cancer
Pancreatic cancer, the 4th leading cause of cancer death in the
US with a 5-year survival of 6% [14], progresses though a series
of pre-neoplastic lesions with characteristic genetic alterations
[15]. Activating Kras mutations are the most common initiating
event and are found in >95% of pancreatic cancers [16]. Kras acti-
vation is typically followed by loss of tumor suppressors, including
p16INK4a [17], p53 [18] and Smad4 [12] that then allow progression
of pre-neoplastic lesions to full malignancy. Smad4 loss occurs late
in the development of pancreatic cancer [19] and has been associ-
ated with metastatic disease [20]. Although both Smad4 mutation
[21] and reduced expression [22] have been independently associ-
ated with reduced survival, the relationship between reduced
Smad4 expression and worse clinical outcome has not been consis-
tently observed [23].
Although Smad4 was initially identiﬁed as DPC4 [12] and is lost
in at least 55% of pancreatic cancers through a combination of loss
of heterozygosity (LOH) [12] and intragenetic mutation [21], in the
presence of multiple other mutations (Kras activation, p16INK4 loss,
p53 loss), the role of Smad4 loss in human pancreatic cancer can
only be evaluated at a correlative level. Since the rate of reduced
Smad4 immunostaining (57%) is similar to that of genetic loss
(deletion (45%) plus mutation (38%), see Table 1), genetic loss ap-
pears to explain the bulk of reduced Smad4 expression in pancre-
atic cancer. Germline Smad4 mutations are not associated with
pancreatic tumors in humans [13], suggesting that Smad4 loss
does not initiate human pancreatic cancer formation.Several groups have used pancreatic-speciﬁc Cre recombinase
strategies to study the role of Smad4 loss in both initiating and
promoting pancreatic cancer development. Smad4 deletion
mediated by the pancreas-speciﬁc Pdx1-Cre driver [24] or
Ptf1a(p48)-Cre driver [25] had no discernible effect on pancreatic
development and did not initiate pancreatic tumors formation in
mice out to 70 weeks of age. However, Smad4 loss markedly
promoted tumor development initiated by KrasG12D activation
and KrasG12D.Smad4/ tumors exhibited both increased prolifer-
ation and tumor stromal formation [26]. Interestingly, Smad4 dele-
tion increased the proportion of well-differentiated tumors
initiated by a combination of Kras activation and p16Ink4a deletion
[26], suggesting that TGFb/Smad4 signaling promotes epithelial–
mesenchymal transition (EMT) and that Smad4 loss prevents
de-differentiation and EMT. Nevertheless, Smad4/ tumors
metastasized more frequently than Smad4+/+ tumors, suggesting
that EMT does not always correlate with metastasis and is not
the primary form of tumor invasion driven by Smad4 loss [27].
Two other studies conﬁrmed that Smad4 deletion accelerated
KrasG12D-initiated pancreatic tumor formation and also reported
that Pdx-Cre.KrasG12D.Smad4/ mice develop squamous cell
carcinomas in the forestomach or distal esophagus as well as
mucinous pancreatic lesions [27,28]. Mechanistically,
KrasG12D.Smad4/ pancreatic tumor cells exhibited no genomic
instability [27]. In another study, Smad4 deletion accelerated
growth and progression of hyperplastic pancreatic lesions initiated
by PTEN deletion, perhaps through mechanisms involving
activated Notch signaling and trans-differentiation [29]. In sum,
these studies demonstrate that Smad4 loss cannot initiate pancre-
atic tumor formation, but promotes pancreatic tumor progression
and increases metastases independent of TGFb-mediated EMT.
3. The role of Smad4 loss in upper aerodigestive tract
malignancies: head-and-neck squamous cell carcinoma
(HNSCC) and esophageal squamous cell carcinoma (ESCC)
Squamous cell carcinomas (SCCs) arising from stratiﬁed squa-
mous epithelial tissues of the upper aerodigestive track cause at
least 20,000 deaths per year in US [14]. It has been consistently re-
ported that Smad4 LOH occurs in 30–50% of HNSCC and ESCC
[30–35]. However, Smad4 point mutations are uncommon, occur-
ring in <5% of these malignancies [30,36] (compared to 35% of
pancreatic cancer and 12% of colon cancer; see Table 1). The sig-
niﬁcantly higher rates of LOH compared to mutation are consistent
with genetic abnormalities in human cancer i.e., for an average size
Table 1
Mechanisms of reduced Smad4 expression in pancreatic cancer compared to HNSCC and ESCC.
Pancreatic cancer N/T (reduced) % (Reduced) Associations/notes Ref.
Loss 18q 25/84 30% [12]
15/25 60% [128]
15/35 42% Poor prognosis (w/loss of 12q and 17p) [129]
40/89 44% Reduced survival [21]
105/233 45% Total (from the above reports)
Mutation 6/27 22% [12]
20/38 53% [15]
4/12 33% [130]
30/77 38% Total (from the above reports)
mRNA 6/21 29% [131]
IHC 9/18 50% [132]
39/59 66% [133]
138/249 55% Reduced survival [22]
63/119 52% Improved survival after resection [134]
8/34 24% Reduced differentiation, stage IV [135]
75/88 85% Nodal involvement, reduced survival [131]
40/65 61% Metastases [20]
65/124 52% Increased vessel density, improved survival [136]
437/756 57% Total (from the above reports)
HNSCC





47/135 35% Total (from the above reports)
Mutation 1/32 3% [30]
mRNA 31/36 86% Versus normal controls [34]
IHC 38/170 22% LN metastases [38]
61/108 61% Grade, LN metastases [39]
41/117 35% Total (from the above reports)
ESCC
LOH 18q 5/14 35% [35]
mRNA 97 NA Non-response to chemo [137]
70 NA Higher stage, worse prognosis [41]
IHC 174/258 67% LN mets, higher stage [40]
41/80 51% Invasion, higher stage [41]
215/338 63% Total (from the above reports)
N/T: Number of reduced cases versus total cases examined. Pancreatic data are for pancreatic ductal adenocarcinoma only (not mucinous cystic neoplasms and intraductal
papillary mucinous neoplasms). In some instances insufﬁcient data were provided to calculate a frequency of reduction.
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mutations occur at a rate of 107 per cell division [37]. In both
HNSCC and ESCC, reduced Smad4 immunostaining is associated
with more aggressive tumor behavior [38–41]. However, reports
of reduced Smad4 expression in human HNSCC and ESCC vary sig-
niﬁcantly from as low as 12% (Xie et al., in press; M. Reiss personal
communication) to as high as 86% [34]. These differences are likely
explained by a combination of the criteria used to deﬁne reduced
Smad4 expression and the control group against which Smad4
expression was compared (i.e., adjacent non-malignant tissue ver-
sus normal tissue from unrelated individuals). For instance com-
plete Smad4 protein loss was reported in 12% of HNSCC (Xie
et al., in press; M. Reiss personal communication) and 63% of ESCC
[40,41] while reduced Smad4 protein has been reported in 35% of
HNSCC [38,39] (see Table 1). When we compared HNSCC and
non-malignant adjacent mucosa with oral mucosa from patients
without cancer, we found reduced Smad4 mRNA expression in
31/36 (86%) of HNSCC samples and in 24/36 (67%) of non-malig-
nant adjacent mucosa [34]. Importantly, Smad4 immunostaining
correlated with reduced mRNA expression [34]. We used a 50%
reduction of mRNA expression to classify individual samples as
‘‘reduced’’ based on the ﬁnding that Smad4 haploid insufﬁciency
promoted tumor development in our HNSCC animal model [34](see below). Using these same criteria, had we compared Smad4
mRNA expression in tumors to adjacent non-malignant mucosa
where Smad4 reduction has already occurred in some cases, we
would have reported signiﬁcantly less Smad4 reduction in HNSCC
(17/36 or 47%) [34]. Since loss of at least one Smad4 copy has been
consistently reported in 30–50% of HNSCC [31–34], reduced Smad4
immunostaining in less than 30% of HNSCC cases should raise
questions about antibody speciﬁcity. Further, it remains to be
determined if patient population, etiological factors (e.g., tobacco
versus HPV), or sample storage method or length of time poten-
tially contribute to the variation reported with reduced Smad4 in
HNSCC.
In contrast to pancreatic cancer, our ﬁnding of Smad4 downreg-
ulation in preneoplastic oral mucosa suggests that Smad4 down-
regulation is an early event in human HNSCC development. To
understand the role of Smad4 loss in HNSCC, we deleted Smad4
speciﬁcally in mouse oral epithelia and found that Smad4 loss
caused spontaneous HNSCC formation [34]. Although deletion of
a single Smad4 allele did not initiate HNSCC formation, it markedly
accelerated HNSCC development initiated by oncogenic KrasG12D
activation [34], suggesting that Smad4 haploid insufﬁciency with
a commensurate 50% Smad4 protein reduction could promote
oncogene-initiated tumor development. Similarly, Smad4 haploid
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deletion initiated hyperplasia [42]. With the observation that
Smad4 downregulation occurs early in HNSCC development, these
studies show that, in contrast to pancreatic cancer, Smad4 loss can
initiate HNSCC formation.
One of our most intriguing ﬁndings may explain why Smad4
deletion initiated HNSCC development: in oral mucosa and HNSCC,
Smad4 deletion down-regulates the Fanc/Brca (Fanconi anemia
complementation/breast cancer susceptibility) genes critical for
maintaining genomic stability [34]. Germline mutations within
this pathway cause Fanconi anemia (FA) and while many FA pa-
tients die of chromosome instability-associated bone marrow fail-
ure as children [43], bone marrow transplants have allowed more
FA patients to survive to adulthood where they subsequently they
have a risk of HNSCC 500 to 700-fold higher than the general pop-
ulation and develop tumors at a median age of 27 years [44].
Smad4-loss dependent downregulation of Fanc/Brca expression
and subsequent genomic instability may allow the accumulation
of the genetic defects required for HNSCC initiation. Our study
showed that downregulation of Fanc/Brca genes occurred within
pre-malignant Smad4/ oral epithelium, well before the devel-
opment of overt malignancy, and Smad4/ HNSCC had increased
genomic instability as evidenced by increased centrosome number,
genomic aberrations by aCGH, and sensitivity to the DNA damag-
ing agent mitomycin C [34], all of which are characteristic of FA
cells [44]. In addition, forced Smad4 expression in a Smad4-deﬁ-
cient cell line increased Brca1 and Rad51 expression with a com-
mensurate increase in the appearance of these molecules at DNA
repair nuclear foci [34]. Importantly, in human HNSCC and non-
malignant adjacent oral epithelium, reduced Smad4 immunostain-
ing correlated with reduced immunostaining for both Brca1 and
Rad51 [34], suggesting that Fanc/Brca downregulation after re-
duced Smad4 expression also occurs in human HNSCC. Since mice
with single Fanc gene deletions do not develop HNSCC [45], it is
possible that downregulation of multiple Fanc/Brca genes after
Smad4 loss eliminates functional compensation among Fanc/Brca
complementation groups, hence facilitating HNSCC initiation. Our
study also suggests intrinsic differences in the role of Smad4 regu-
lation of Fanc/Brca, and consequently genomic stability, in the
upper and lower digestive tract (or stratiﬁed versus simple epithe-
lia layers). Although Smad4 loss is common late in pancreatic and
colon cancer, targeted Smad4 deletion to the pancreas did not ini-
tiate pancreatic cancer [24,25], perhaps because Smad4 does not
regulate Fanc/Brca genes in simple epithelium; a hypothesis is sup-
ported by the observation that Smad4/ pancreatic tumors did
not exhibit genomic instability [27]. An alternative hypothesis,
which is supported by the observation that FA patients do not have
an increased incidence of colon or pancreatic cancer, despite their
susceptibility to HNSCC [43], is that, like hematopoietic cells, sim-
ple epithelial cells with Fanc/Brca down-regulation (regardless of
whether mediated by Smad4 loss or not) may undergo apoptosis
that prevents them from developing into cancer.
Another potential mechanism related to the initiation capacity
of Smad4 loss in HNSCC is Smad4 loss-associated inﬂammation.
Mice with Smad4 deletion in T cells developed inﬂammation in
the gastrointestinal tract and lower intestinal malignancies remi-
niscent of juvenile polyposis (JP) as well as oral SCCs [46]. Similarly,
our murine Smad4/HNSCC have increased expression of inﬂam-
matory cytokines with an associated inﬁltration of neutrophils, T
cells, and Th17 cells [34]. Interestingly, Smad4 loss-associated sub-
mucosal inﬂammation was abrogated in a Smad3+/ background,
suggesting that inﬂammation in Smad4/ HNSCC requires
Smad3-dependent TGFb signaling. Supporting this notion,
Smad4/ HNSCC expressed more TGFb1 ligand and had evidence
of increased signaling through both Smad3 and phospho-Smad1/5/
8 in tumor epithelial cells [34], consistent with increased BMPsignaling after TGFb signaling disruption [47]. Hence, it is likely that
Smad3-dependent inﬂammation after Smad4 deletion reﬂects
Smad3-mediated chemokine/cytokine production by epithelial
cells. Consistent with our study, loss of pSmad2/3 staining in hu-
man HNSCC was associated with improved survival (Xie et al., in
press; M. Reiss personal communication), further supporting the
tumor promoting effect of epithelial Smad3 activation in human
HNSCC. These studies also highlight the context-speciﬁc nature of
TGFb signaling in immune response, as Smad3 loss in T cells abro-
gates TGFb-induced immune suppression [48] while Smad3 loss
in epithelial cells abrogates pro-inﬂammatory TGFb actions [34].
Consistent with the ﬁnding in pancreatic cancer that Smad4 is
required for TGFb-mediated EMT but that EMT is not always re-
quired for metastasis, Smad4/ SCCs do not undergo early-stage
EMT [49] but retain the ability to metastasize [34]. Similarly,
although ESCC induced by simultaneous PTEN and Smad4 deletion
retain terminal differentiationmarkers early in carcinogenesis, they
also metastasize [42]. That Smad4/ tumors retain the ability to
metastasize in the absence of EMT, suggests that Smad4 loss pro-
motes metastases through other mechanisms such as increased
inﬂammation and angiogenesis within the tumor associated stro-
ma. Overall the phenotype of murine Smad4/ HNSCC (reduced
FA/Brca expression, lack of EMT) suggests that human HNSCC with
reduced Smad4 expression may be more sensitive to speciﬁc
therapies. For example, epidermal growth factor receptor (EGFR)
inhibitors are more effective in HNSCCs that retain E-cadherin
expression [50] and poly(ADP-ribose) polymerase (PARP) inhibitors
are more effective in tumors with Fanc/Brca defects [51,52].4. Smad4 loss in cancers similar to pancreatic cancer: colon
cancer, cholangiocarcinoma, and prostate cancer
Colorectal cancer, is the 2nd leading cause of cancer death with
140,000 new cases and 50,000 deaths per year in the US [14],
and also progresses through a series of pre-neoplastic lesions with
well-known genetic alterations [53,54]. Polyp formation is typically
initiated by APC (adenomatous polyposis coli) gene inactivation
[55,56]; Kras mutation and p53 inactivation then allow adenoma
growth and progression to carcinoma [57,58]. Similar to pancreatic
cancer, Smad4 loss occurs through a combination of genetic
deletion ormutation, is present in40–50% of colon cancers, occurs
around the transition from benign to invasive carcinoma [59], and
is associated with metastasis, advanced disease, and reduced
survival [60–63]. Although germline Smad4 mutations are found
in 20% of juvenile polyposis (JP), a rare autosomal disease charac-
terized by numerous intestinal polyps and a lifetime colon cancer
risk of 50% [13], not all germline Smad4 mutations cause JP [64].
Inmice, homozygous germline Smad4 deletion is lethal between
embryonic days 6.5 and 8.5 due to failure of mesoderm induction
[65,66]. Consistent with JP caused by heterozygous Smad4 loss in
humans, mice with heterozygous germline Smad4 deletion also
develop inﬂammatory polyps in the glandular stomach and duode-
num beginning at about 1y of age [67,68]. These polyps occur after
loss of the second Smad4 allele, have an inﬂammatory stromal
component that resembles the polyps seen in human JP [69], and
can eventually degenerate into carcinoma [67,68]. The long latency
of inﬂammatory polyp formation suggests that epithelial Smad4
loss alone may be insufﬁcient for tumor initiation. Supporting this
notion, Smad4 deletion in T cells causes intestinal inﬂammation
and intestinal tumors that are also reminiscent of the lesions seen
in human JP [46], suggesting that Smad4 signaling in T cells plays
a critical role in tumor suppression, particularly in the GI tract,
and that tumorigenesis in JP or heterozygous germline Smad4
deletion may be related to Smad4 loss in the immune system as
opposed to Smad4 loss in epithelial cells [70]. Similar to pancreatic
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colon cancer. Heterozygous Smad4 loss promotes the development
of colon cancers initiated by germline APC gene deletion [66] and
APC+/Smad4/ tumors recruit immature CD34+/CCR1+myeloid
cells to the tumor front that then promote tumor invasion [71],
again suggesting inﬂammation as an important component of colon
cancer initiation. In aggregate, both clinical and animal studies sug-
gest that Smad4 loss in simple epithelia may not initiate cancer for-
mation, but clearly promotes cancer growth and progression.
Conversely, while JP patients with heterozygous Smad4 mutations
are markedly susceptible to colon cancer, they do not have an in-
creased incidence of HNSCC or other cancers arising from squamous
epithelia [13], implying that loss of one Smad4 allele does not select
mutant Fanc/Brca cells for outgrowth or is insufﬁcient to down-
regulate the Fanc/Brca pathway and cause tumor formation in
head-and-neck tissue.
Other mouse models of Smad4 deletion have deepened and sup-
ported the ﬁndings outlined above. For example, Smad4 deletion
targeted to the liver with an albumin-Cre driver did not initiate
cholangiocarcinoma formation but homozygous Smad4 deletion
promoted development of cholangiocarcinoma initiated by PTEN
deletion [72]. This suggests the role of Smad4 in cholangiocarci-
noma and pancreatic cancer may be similar; that Smad4 immuno-
staining is lost in 45% of cholangiocarcinomas and is associated
with more aggressive tumor behavior supports this idea [73]. A
similar pattern occurs in prostate cancer. Prostate speciﬁc Smad4
deletion did not initiate cancer formation but increased both pros-
tate cancer progression initiated by PTEN deletion and the fre-
quency of metastases to local lymph nodes and lung [74]. Similar
to SCCs [75,76], cyclin D1 upregulation maymediate tumor promo-
tion after Smad4 loss in pancreatic cancer [74]. In human prostate
cancer, Smad4 LOH occurs in 25% of cases [77] and Smad4 muta-
tions are uncommon [77], but promoter methylation may contrib-
ute to reduced Smad4 expression [78].
5. Smad4 loss in cancers similar to HNSCC: SCCs arising from
skin and mammary glands
Similar to HNSCC, we found Smad4 LOH in 57% of human skin
SCCs with reduced Smad4 immunostaining in 70% [49]. Although
it remains to be determined whether Smad4 downregulation oc-
curs early in skin SCC, various mouse models show that Smad4 loss
can initiate skin SCC. Keratinocyte-speciﬁc Smad4 deletion
mediated by K5-Cre interrupted hair follicle cycling causing hyper-
proliferative hair follicles, progressive hair loss, and predominantly
well-differentiated skin SCCs consistent with both the role of
Smad4 as an in initiator in stratiﬁed epithelia and the critical role
of Smad4 in mediating TGFb-dependent EMT [75]. Smad4 deletion
driven by mouse mammary tumor virus (MMTV)-Cre caused a
similar skin phenotype with hair loss, disruption of hair follicle
differentiation, and the formation of well-differentiated SCC [76].
Our unpublished data reveal that Smad4 loss initiates tumor
formation by disrupting DNA repair mechanisms similar to that
observed in HNSCC. Similar to HNSCC, Smad4 loss activates sur-
vival factors including increased AKT signaling, activation of cyclin
D1, and increased c-myc expression [75,76] which promotes the
growth of Smad4/ skin stem cells resulting the development
of multiple cancer types including sebaceous adenomas and basal
cell carcinomas [75,76]. Smad4 loss also promotes PTEN deletion-
initiated skin tumor formation [75]. Similar to HNSCC, Smad4/
skin SCC has increased angiogenesis and inﬂammation [79].
Interestingly, Smad4 deletion targeted to the mammary gland
(by either MMTV-Cre or WAP-Cre) causes mammary abscesses
and mammary tumors with transdifferentiation to squamous
histology and blockade of EMT [80]. These data clearlydemonstrate that Smad4 loss initiates SCC formation and promotes
tumor progression through increased inﬂammation and angiogen-
esis while preventing TGFb-dependent EMT.
6. Smad2 loss and cancer
Smad2 maps to 18q21, near the Smad4 locus [81]; however,
Smad2 genetic losses have not been described in pancreatic cancer.
Although Smad2 mutations occur infrequently in colon cancer
(5%) [81,82], reduced Smad2 immunostaining has been associ-
ated with shortened survival [83]. Germline Smad2 deletion in
mice is embryonic lethal due to gastrulation failure [84–87], but
Smad2 heterozygotes are viable, fertile, and do not develop spon-
taneous tumors [88]. Smad2 deletion has not been speciﬁcally tar-
geted to either the pancreas or colon but Smad2+/APC+/
compound heterozygotes had larger and more invasive colonic tu-
mors than APC+/ controls without an increase in tumor number
[88]. These studies suggest that while Smad2 functions as a tumor
suppressor in cancers arising from simple epithelia, Smad2 loss
alone is insufﬁcient to initiate tumor formation.
Smad2 downregulation is more common in SCCs than in simple
epithelial tumors. Although Smad2 mutations and deletions are
infrequent in both primary HNSCC and HNSCC cell lines
[32,89,90], Smad2 LOH was detected in 63% of HNSCC cell lines
[33]. Similarly, we found that 70% of skin SCCs (and 100% of poorly
differentiated skin SCCs) had reduced Smad2 immunostaining [49].
Among poorly differentiated skin SCCs, 94% had a >50% reduction
in Smad2 mRNA expression compared to normal skin; of these
samples, 67% exhibited Smad2 LOH [49]. These observations show
that while Smad2 mutations and deletions are uncommon in SCCs,
Smad2 LOH is frequent and associated with reduced Smad2
expression and de-differentiation. That reduced Smad2 expression
is far more common in poorly differentiated skin SCC [49] suggests
a role in SCC progression rather than initiation. Like Smad4, the
incidence of reduced Smad2 immunostaining in human SCC varies
widely from 14% of HNSCC with absent Smad2 immunostaining
[38] to 70% of skin SCCs with reduced Smad2 immunostaining [49].
To understand the role of Smad2 in skin carcinogenesis we
targeted Smad2 deletion to epithelial cells using a keratin 5
(K5) promoter [49,91]. While neither K5.Smad2/ nor
K5.Smad2+/ mice developed spontaneous skin tumors, when
subjected to a two-stage chemical skin carcinogenesis protocol
both K5.Smad2/ and K5.Smad2+/ animals exhibited acceler-
ated tumor formation with earlier malignant conversion, increased
EMT, and reduced differentiation [49]. Similarly, germline
Smad2+/ mice did not develop spontaneous tumors, but had in-
creased susceptibility to chemical skin carcinogenesis and also de-
velop more poorly differentiated tumors [92]. These data suggest
that Smad2 exhibits haploid insufﬁciency with respect to tumor
suppression, a criteria that should be taken into consideration
when analyzing Smad2 downregulation in human cancer samples.
Mechanistically, we found that Smad2 loss increased Smad3/4
binding at the Snail SBE, leading to increased Snail expression
and reduced E-cadherin [49]. In addition, both Smad2/ skin
SCCs and Smad2/ non-malignant murine skin had increased
angiogenesis through a similar mechanism involving increased
hepatocyte growth factor (HGF) expression [91] and human skin
and head and neck SCC with reduced Smad2 expression also have
higher HGF expression [91]. In contrast to Smad4/ SCCs,
Smad2/ SCCs did not have increased expression of either TGFb
or VEGF [91]. This suggests that tumors with reduced Smad2
expression may be susceptible to HGF-targeted treatment, a
hypothesis supported by our study showing that short term treat-
ment of Smad2/ skin with a c-Met (HGF receptor) inhibitor
reduces Smad2 loss-associated angiogenesis [91].
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cervical cancer, and hepatocellular carcinoma [93–95]. Targeted
Smad2 disruption in T cells reduced Th17 cell differentiation
[96,97] and Smad2 deletion in B cells prevented immunoglobulin
class switching [98] but tumors were not described in any of these
models. This is in contrast to the tumor formation seen after
Smad4 deletion in T cells [46] and suggests different roles for
Smad2 and Smad4 in immune cell homeostasis and tumor sup-
pression. Other studies have also consistently shown that Smad2
deletion in various tissues (central nervous system, kidney, ovary,
liver) is insufﬁcient to initiate tumor formation [99–102]. Similar
to our observation in skin carcinogenesis, Smad2 deletion in
hepatocytes did not affect liver development or cause tumors but
Smad2/ hepatocytes undergo spontaneous EMT and have in-
creased migration and proliferation in vitro [102]. In sum, Smad2
loss alone is insufﬁcient for tumor initiation but promotes tumor
progression through increased EMT and angiogenesis.
7. The role of Smad3 in cancer
Smad3 is located at 15q22 and mutations are associated with
familial thoracic aortic aneurysms [103]. Smad3 mutations were
not initially found in either human colon cancer or pancreatic can-
cer [104], though subsequent analyses identiﬁed a low frequency
of Smad3 mutations in colon cancer [82]. The clinical signiﬁcance
of Smad3 mutations is unclear as other reports describe increased
Smad3 immunostaining in colon cancer [105] and increased phos-
pho-Smad3 immunostaining in ulcerative colitis lesions [106], sug-
gesting that activated TGFb/Smad3 signaling may be present in, and
contributing to, these inﬂammatory lesions. While one of three
independently described germline Smad3 knockout mouse models
developed metastatic colon carcinomas [48,107,108], a later study
suggested that colon tumor formation in these animals required
chronic helicobacter infection that drove local inﬂammation
[109]. Although Smad3 germline deletion increased multiplicity
of APC initiated tumors in the distal colon [110], it is unclear
whether this related to Smad3 loss in colonic mucosa or Smad3
loss in immune cells, particularly since Smad3/ animals exhib-
ited chronic intestinal inﬂammation [48] that could have promoted
APC-initiated tumors.
Similarly, Smad3 mutations are rare in human HNSCC [30] and
reduced Smad3 immunostaining is uncommon (0–7%) in HNSCC,
ESCC, and skin SCC (Xie et al., in press; M. Reiss personal communi-
cation) [49,111]. Smad3may be tumor suppressive in keratinocytes
as suggested by the observation that Smad3 deletion increased SCC
formation of grafted, v-H-ras-transduced keratinocytes [112]. How-
ever, Smad3+/ and Smad3/mice are resistant to chemical skin
carcinogenesis [92,113] and we found that Smad3/ skin tumors
have reduced inﬂammation [113], again suggesting that Smad3
mediates TGFb-induced inﬂammation. Keratinocyte molecular pro-
ﬁling demonstrates that Smad3 mediates expression of both tumor
suppressive and tumor promoting TGFb-responsive genes [114];
however, on balance, it appears that the inﬂammatory actions of
Smad3 are more potent than its tumor suppressive actions. Smad3
deletion accelerates both skin and oral wound healing by reducing
local inﬂammation [115,116] but conversely, impairs colonic
wound healing [117]. Because these models all employed germline
Smad3 deletion, it cannot be discerned if the observed effects are
related to Smad3 loss in the epithelium or in the immune cells re-
cruited to these different anatomic locations. Nevertheless, these
studies highlight the context-speciﬁc nature of Smad3 function in
inﬂammation.
The role of Smad3 in other malignancies is less clear. Smad3
mutations are infrequent in human lung and breast cancer
[82,104,118]; however, reduced Smad3mRNAor protein expressionhas been seen in endometrial cancer, gastric cancer, and parathyroid
adenomas [119–121]. The best evidence for Smad3 as a tumor sup-
pressor in human cancer comes from pediatric T cell acute lympho-
blastic leukemiawhere there is noSmad3proteinexpressiondespite
the absence of Smad3 mutations [122]. Animal data is similarly
sparse. Forced Smad3 expression in hepatocytes protects against
chemical liver carcinogenesis by promoting apoptosis through
Bcl2 [123], suggesting a tumor suppressive role for Smad3 inmouse
liver carcinogenesis. In contrast, Smad3 deletion slows gonadal tu-
mor development in inhibin null mice [124], suggesting a tumor
promoting role in this setting. In sum, to better deﬁne the roles of
Smad3 in variousmalignancies will require additional studies more
speciﬁcally targeting Smad3 loss or overexpression to speciﬁc cell
types or tissues.
8. Implications of signaling Smad status in cancer therapy
Research on TGFb signaling Smads in cancer has revealed their
diverse roles at many levels: individual signaling Smads have
different roles in a given cancer, while the same Smad can have
different roles depending on the cancer type. Because the levels
and functions of Smads are tightly regulated, reduced expression
of one Smad can critically affect this balance such that while
individual Smads (particularly Smads 2 and 4) are generally tumor
suppressive, hyperactivation of Smad2, 3, and 4 can promote EMT
[49,125] and angiogenesis [79,91] (see Fig. 2). Additionally, altera-
tions in each Smad could affect the balance between Smad-depen-
dent and Smad-independent TGFb signaling, and many of the
Smad-independent TGFb pathways are potentially oncogenic [10].
These dynamic and complex relationships make directly targeting
Smads for cancer therapy challenging. However, the downstream
or alternative pathways activated after Smad loss are potential
therapeutic targets, meaning that Smad status is a biomarker for
drug susceptibly. For example, Brcamutant breast cancers aremore
sensitive to PARP inhibitors that prevent DNA repair and induce
DNA damage-associated cell death [51,52]. Since Smad4/ kerat-
inocytes have reduced Fanc/Brca expression and are similarly
sensitive to DNA damage, it will be interesting to see whether
HNSCC with reduced Smad4 expression are similarly sensitive to
PARP inhibitors. Of note, this type of targeted therapy may not be
applicable to all Smad4 deﬁcient cancers, speciﬁcally pancreatic
and colon cancers, where Smad4 loss is not associated with
genomic instability [27]. Smad4/ SCCs also have increased
TGFb-mediated inﬂammation and VEGF-driven angiogenesis
[34,79], suggesting that targeting the tumor stroma with a TGFb
receptor inhibitor or a VEGF inhibitor might be effective. Finally,
we have also shown that short-term treatment with a c-Met inhib-
itor reduces Smad2 loss-associated angiogenesis [91]; it remains to
be seen if c-Met inhibitors have clinical efﬁcacy in human tumors
with reduced Smad2 expression.
9. Future perspectives
Although the frequency of genetic alteration or reduced Smad
expression are comparable between cancers arising from simple
(pancreatic/colon) and stratiﬁed epithelial layers (SCCs), numer-
ous studies show that the consequences of reduced Smad expres-
sion (particularly Smad4) differ signiﬁcantly among these
malignancies and suggest that this could substantially alter the
therapeutic strategies employed to target these cancers. Well con-
trolled clinical trials that include measurement of relevant bio-
markers will be required to determine which of these basic
scientiﬁc observations are ultimately relevant to cancer treat-
ment. Additionally, studies in other cancer types will be required
to determine which model of Smad4 loss they follow. For
Fig. 2. Roles of Smads identiﬁed in SCCs. In non-malignant epithelial tissues, Smads function as tumor suppression. Smad2 loss promotes tumor progression through
increased EMT and increased HGF while Smad4 loss promotes tumor progression through increased angiogenesis and inﬂammation mediated by increased VEGF and TGFb
expression, respectively. In addition, Smad4 loss initiates SCC formation in stratiﬁed epithelial layers via downregulation of Fanc/Brca family members.
1990 S.P. Malkoski, X.-J. Wang / FEBS Letters 586 (2012) 1984–1992example, will breast cancers harboring Smad4 mutations [126] be
as sensitive to PARP inhibitors as Brca-mutant breast or ovarian
cancers? Similar questions exist for lung cancer where Smad4
mutations also occur [127], but the Smad4 loss phenotype has
not been determined. In addition, Smad4 being more frequently
inactivated in HPV-positive tumors [128], suggests that different
mutagens could affect TGFb signaling and hence impact targeted
treatment paradigms. In sum, the TGFb/Smad ﬁeld is moving clo-
ser to translating outstanding basic science discoveries into ther-
apeutic cancer strategies.
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